Journal of Down Syndrome & Chromosome Abnormalities
Open Access

Placental Chromosomal Abnormalities on Fetal Development and Pregnancy Outcomes

Takol Guichet^{* *}Correspondence: Takol Guichet, Department of Pathology, Institute of Health and Science, Mahidol University, Bangkok, Thailand, Email:

Author info »

Description

Placental chromosomal abnormalities represent a significant subset of genetic disorders that can deeply impact fetal development and pregnancy outcomes. The placenta an interacting organ important for supporting fetal growth and development plays a pivotal role in ensuring the exchange of nutrients, oxygen and waste products between the mother and the fetus [1]. When chromosomal abnormalities occur within the placental tissue they disrupt these essential functions leading to a spectrum of developmental complications and pregnancy challenges. It explains the mechanisms clinical implications, diagnostic strategies, management approaches and future directions related to placental chromosomal abnormalities aiming to provide a comprehensive understanding of their impact on fetal development and pregnancy outcomes.

Changes in the quantity or organization of chromosomes which hold the genetic material required for proper cellular growth and function are referred to as chromosomal abnormalities. These abnormalities can arise due to errors during the formation of reproductive cells (sperm and egg) or early stages of embryo development [2]. In the context of placental chromosomal abnormalities these genetic anomalies affect the cells within the placental tissue influencing its structure, function and ability to support fetal growth.

Types of Placental Chromosomal abnormalities

Trisomies: In trisomies there is an extra copy of a chromosome. Common examples include Trisomy 13 (Patau syndrome) Trisomy 18 (Edwards syndrome) and Trisomy 21 (Down syndrome). These conditions result in developmental disabilities, congenital anomalies and often severe medical complications affecting multiple organ systems.

Monosomies: Monosomies involve the absence of one copy of a chromosome. Monosomy X (Turner syndrome) is an example where females have only one X chromosome instead of the typical two leading to developmental delays and specific physical features [2].

Mosaicism: Mosaicism refers to the presence of cells with different chromosomal compositions within the same individual. In placental mosaicism this variability can lead to unpredictable clinical presentations and challenges in diagnosis and management [3].

Impact on fetal development

Placental chromosomal abnormalities exert their effects through several mechanisms that disrupt normal placental function and fetal development:

Structural and functional impairments: Chromosomal abnormalities alter the genetic instructions necessary for placental development and function. As a result the placenta may exhibit structural abnormalities or functional deficits impairing its ability to adequately support fetal growth and nutrient exchange. This can lead to conditions such as Intrauterine Growth Restriction (IUGR) where the fetus fails to achieve expected growth milestones.

Developmental deficits and anomalies: The genetic disruptions caused by chromosomal abnormalities can result in developmental delays and congenital anomalies affecting various organ systems. For example Trisomy 18 is associated with heart defects, kidney abnormalities and characteristic physical features like clenched fists and overlapping fingers while Trisomy 21 (Down syndrome) manifests with intellectual disabilities, distinctive facial features and increased susceptibility to certain health conditions [4].

Pregnancy complications: Placental chromosomal abnormalities increase the risk of pregnancy complications that can impact maternal health and fetal well being.

Miscarriage: Chromosomal abnormalities are a leading cause of early pregnancy loss contributing to miscarriages during the first trimester when fetal development is most vulnerable [5].

Stillbirth: In severe cases placental chromosomal abnormalities may lead to intrauterine fetal demise resulting in stillbirth before or during labor.

Preterm Birth: Placental dysfunction and inadequate fetal support can precipitate preterm labor increasing the risk of neonatal complications and long term health consequences for the baby.

Diagnostic approches

Ultrasound: Routine prenatal ultrasound can detect structural abnormalities or growth restrictions suggestive of chromosomal disorders [6].

Maternal serum screening: Blood tests measuring specific markers can indicate an increased risk of chromosomal abnormalities prompting further diagnostic testing.

Chorionic Villus Sampling (CVS): CVS involves obtaining a small sample of placental tissue for genetic analysis typically performed between 10 to12 weeks of pregnancy.

Amniocentesis: Amniocentesis involves sampling the amniotic fluid surrounding the fetus to analyze fetal cells for chromosomal abnormalities typically performed after 15 weeks of pregnancy [7].

Genetic counseling: Genetic counseling plays a important role in providing information, support and guidance to families facing a diagnosis of placental chromosomal abnormalities. Counselor’s help parents understand the implications of genetic findings discuss reproductive options and facilitate informed decision making regarding prenatal testing and pregnancy management.

Management and care strategies

Fetal growth assessment: Regular ultrasound examinations monitor fetal growth and development assessing for signs of IUGR or other complications associated with placental dysfunction [8].

Maternal health monitoring: Close monitoring of maternal health including blood pressure monitoring and laboratory assessments helps identify and manage pregnancy related complications such as preeclampsia.

Team approach: Collaborative care involving obstetricians, maternal fetal medicine specialists, geneticists, neonatologists and other healthcare professionals ensures comprehensive management of maternal and fetal health.

Individualized care plans: Modifying care plans based on specific genetic findings, pregnancy progression and maternal fetal risks optimizes outcomes and supports informed decision making.

Informed choice: Providing expectant parents with accurate information about the prognosis and potential outcomes associated with placental chromosomal abnormalities supports informed reproductive decision making.

Ethical dilemmas: Ethical considerations arise regarding the scope of prenatal testing, the implications of genetic results and the autonomy of parents in making decisions that align with their values and beliefs [9,10].

Conclusion

In conclusion placental chromosomal abnormalities represent a complex spectrum of genetic disorders with significant implications for fetal development and pregnancy outcomes. Through a multidisciplinary approach surrounding prenatal screening, genetic counseling, personalized care plans and supportive interventions healthcare providers can optimize management strategies and support families facing the challenges associated with these conditions. Advancements in genomic technologies such as Non-invasive Prenatal Testing (NIPT) and whole-genome sequencing show potential for improving early detection and understanding the genetic mechanisms underlying placental chromosomal abnormalities. Ongoing study efforts aim to refine diagnostic strategies, enhance prenatal care practices and search potential therapeutic interventions to mitigate the impact of these conditions on fetal development and pregnancy outcomes. Continued studies and collaborative efforts are essential to advance knowledge, refine diagnostic capabilities and ultimately improve outcomes for both mothers and their babies affected by placental chromosomal abnormalities.

References

1. Ortega MA, Fraile-Martínez O, García-Montero C, Sáez MA, Álvarez-Mon MA, Torres-Carranza D, et al. The pivotal role of the placenta in normal and pathological pregnancies: a focus on preeclampsia, fetal growth restriction, and maternal chronic venous disease. Cells. 2022;11(3):568.

   [Crossref] [Google scholar] [PubMed]
   

2. Goldwaser T, Klugman S. Cell-free DNA for the detection of fetal aneuploidy. Fertil Steril. 2018;109(2):195-200. 

   [Crossref] [Google scholar] [PubMed]
   

3. Munné S, Weier HU, Grifo J, Cohen J. Chromosome mosaicism in human embryos. Biol Reprod. 1994;51(3):373-379.

   [Crossref] [Google scholar] [PubMed]
   

4. Korenberg JR, Chen XN, Schipper R, Sun Z, Gonsky R, Gerwehr S, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci. 1994;91(11):4997-5001.

   [Crossref] [Google scholar] [PubMed]

5. Pliushch G, Schneider E, Weise D, El Hajj N, Tresch A, Seidmann L, et al. Extreme methylation values of imprinted genes in human abortions and stillbirths. Am J Pathol. 2010;176(3):1084-1090.

   [Crossref] [Google scholar] [PubMed]

6. Borrell A, Stergiotou I. Miscarriage in contemporary maternal-fetal medicine: targeting clinical dilemmas. Ultrasound Obstet Gynecol.  2013;42(5):491-497.

   [Crossref] [Google scholar] [PubMed]

7. Lo YD, Lun FM, Chan KA, Tsui NB, Chong KC, Lau TK,et al.  Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci. 2007;104(32):13116-13121.

   [Crossref] [Google scholar] [PubMed]

8. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-585.

   [Crossref] [Google scholar] [PubMed]

9. Siani M, Assaraf OB. Should I perform genetic testing? A qualitative look into the decision making considerations of religious Israeli undergraduate students. J Genet Couns. 2016;25(5):1093-1115.

   [Crossref] [Google scholar] [PubMed]

10. Gregg AR, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, et al. ACMG Noninvasive Prenatal Screening Work Group. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18(10):1056-1065.

    [Crossref] [Google scholar] [PubMed]